Advertisement
IQV vs RVTY
Which Stock Would AI Choose? IQVIA Holdings Inc. (IQV) vs. Revvity, Inc. (RVTY) Stock Comparison
Key Takeaways
- IQV has delivered stronger year-to-date (YTD) performance of +30.01% compared to RVTY's +10.28%, highlighting superior relative momentum in recent market activity.
- IQV trades at a lower price-to-earnings (P/E) ratio of 20.12 versus RVTY's 42.08, suggesting a relatively more attractive valuation.
- Both stocks operate in the healthcare diagnostics and research sector, but IQV boasts a larger market capitalization of $26.5 billion against RVTY's $9.7 billion.
- IQV's recent AI initiatives and upcoming quarterly earnings have drawn attention, while RVTY focuses on product launches and shareholder governance.
- RVTY offers a modest dividend yield of 0.32%, providing income appeal absent in IQV.
- IQV exhibits higher volatility with a beta of 1.18 compared to RVTY's 1.05, reflecting differing risk profiles.
Introduction
This stock comparison examines IQV and RVTY, two prominent players in the healthcare diagnostics and research sector. Investors and traders focused on healthcare equities may find value in assessing their relative performance, valuations, and market positioning amid evolving industry dynamics like AI integration and product innovation. With both companies navigating recent market volatility, understanding their business models, momentum, and risk factors aids informed decision-making in portfolio allocation or trading strategies. This analysis draws on current data to highlight contrasts for healthcare sector enthusiasts seeking opportunities in stock comparison and relative performance.
IQV Overview and Recent Performance
IQV, or IQVIA Holdings Inc., is the world's largest provider of biopharmaceutical development services and commercial outsourcing services. The company leverages advanced analytics and technology to support pharmaceutical research, clinical trials, and real-world evidence generation. In recent market activity, IQV shares have traded around $158, within a 52-week range of $135 to $247, reflecting notable volatility. Year-to-date gains stand at +30%, driven by robust revenue growth, though recent weeks have seen pressure from valuation concerns, potential share issuance, and AI-related competitive fears despite in-line earnings. Key developments include the launch of IQVIA.ai with NVIDIA and anticipation for first-quarter 2026 results, influencing positive sentiment amid expected earnings per share (EPS) growth.
RVTY Overview and Recent Performance
RVTY, or Revvity, Inc., is a global life sciences and diagnostics company offering tools for discovery, development, and manufacturing in health sciences. It focuses on reagents, instruments, and software for genomics, proteomics, and diagnostics. Recently, shares hover near $87, with a 52-week range of $81 to $118 and YTD performance of +10%. Market sentiment has been mixed, buoyed by shareholder re-elections, quarterly dividend declarations, and innovations like Signals BioDesign for molecular cloning, alongside presentations at investor conferences. However, analyst cautions on revenue trends and valuation have tempered gains in recent weeks, contrasting with occasional sector-driven surges.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available on the platform, selected for their suitability in current market conditions like volatility in tech and healthcare sectors. These bots employ diverse strategies—ranging from short-term scalping (1-day holds) to swing trading (up to 49 days)—delivering impressive stats such as annualized returns of +23% to +163%, win rates from 51% to 88%, and profit factors up to 11.70. While none currently feature IQV or RVTY, they trade thousands of tickers across stocks, ETFs, and crypto with built-in risk management for virtual or brokerage accounts. Traders can copy these signals for automated execution, adapting to various timeframes and styles. Explore the page to identify bots aligning with your market outlook.
Head-to-Head Comparison
In business models, IQV emphasizes services like contract research organization (CRO) activities and data analytics, contrasting RVTY's product-centric approach in life sciences tools and diagnostics. Growth drivers for IQV include AI-enhanced platforms and pharma outsourcing demand, while RVTY benefits from innovation in cancer research and molecular tools. Recent momentum favors IQV with superior YTD returns, though its higher beta signals greater risk versus RVTY's stability. Risk factors encompass competitive pressures and macroeconomic sensitivity for both, with IQV facing dilution concerns and RVTY revenue softness in China. Sector exposure aligns in diagnostics/research, but IQV's lower P/E and higher EPS underscore better profitability positioning, while RVTY's dividend adds income trade-offs. Market sentiment tilts toward IQV's catalysts amid RVTY's mixed analyst views.
Tickeron AI Verdict
Tickeron’s AI analysis would currently favor IQV over RVTY, based on stronger trend consistency, YTD outperformance, attractive valuation multiples, and near-term catalysts like earnings and AI advancements. While RVTY offers stability and yield, IQV's relative positioning suggests higher probability of upside in the prevailing healthcare environment, though volatility warrants caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Buy and RVTY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 6 TA indicator(s) are bullish while RVTY’s TA Score has 6 bullish TA indicator(s).
- IQV’s TA Score: 6 bullish, 3 bearish.
- RVTY’s TA Score: 6 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а +0.07% price change this week, while RVTY (@Medical Specialties) price change was +0.22% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.37%. For the same industry, the average monthly price growth was +13.38%, and the average quarterly price growth was -6.74%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (-2.37% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | RVTY | IQV / RVTY | |
| Capitalization | 30.4B | 11.3B | 269% |
| EBITDA | 3.52B | 773M | 455% |
| Gain YTD | -19.183 | 4.838 | -396% |
| P/E Ratio | 22.63 | 48.70 | 46% |
| Revenue | 16.6B | 2.9B | 572% |
| Total Cash | 2.1B | 860M | 245% |
| Total Debt | 16.1B | 3.35B | 481% |
IQV | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 42 | 28 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (14) in the Medical Specialties industry is somewhat better than the same rating for IQV (63) in the Servicestothe Health Industry industry. This means that RVTY’s stock grew somewhat faster than IQV’s over the last 12 months.
RVTY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that RVTY’s stock grew similarly to IQV’s over the last 12 months.
RVTY's SMR Rating (100) in the Medical Specialties industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that RVTY’s stock grew similarly to IQV’s over the last 12 months.
RVTY's Price Growth Rating (50) in the Medical Specialties industry is in the same range as IQV (50) in the Servicestothe Health Industry industry. This means that RVTY’s stock grew similarly to IQV’s over the last 12 months.
RVTY's P/E Growth Rating (28) in the Medical Specialties industry is in the same range as IQV (42) in the Servicestothe Health Industry industry. This means that RVTY’s stock grew similarly to IQV’s over the last 12 months.
| IQV | RVTY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 66% |
| Momentum ODDS (%) | 2 days ago 61% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 60% |
| Advances ODDS (%) | 2 days ago 58% | 2 days ago 66% |
| Declines ODDS (%) | 16 days ago 65% | 9 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 49% |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | -2.73% | ||
| TMO - RVTY | 69% Closely correlated | -2.43% | ||
| IQV - RVTY | 66% Loosely correlated | -2.19% | ||
| A - RVTY | 66% Loosely correlated | -2.85% | ||
| CRL - RVTY | 65% Loosely correlated | -1.88% | ||
| DHR - RVTY | 64% Loosely correlated | -2.54% | ||
More | ||||